ATE479662T1 - Pyrimidinonverbindungen, ihre herstellung und ihre verwendung - Google Patents

Pyrimidinonverbindungen, ihre herstellung und ihre verwendung

Info

Publication number
ATE479662T1
ATE479662T1 AT05824250T AT05824250T ATE479662T1 AT E479662 T1 ATE479662 T1 AT E479662T1 AT 05824250 T AT05824250 T AT 05824250T AT 05824250 T AT05824250 T AT 05824250T AT E479662 T1 ATE479662 T1 AT E479662T1
Authority
AT
Austria
Prior art keywords
preparation
compounds
pyrimidinone compounds
useful
pyrimidinone
Prior art date
Application number
AT05824250T
Other languages
English (en)
Inventor
Hui Yao
Original Assignee
Hui Yao
Zhejiang Hisun Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hui Yao, Zhejiang Hisun Pharmaceutical filed Critical Hui Yao
Application granted granted Critical
Publication of ATE479662T1 publication Critical patent/ATE479662T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05824250T 2004-12-23 2005-12-23 Pyrimidinonverbindungen, ihre herstellung und ihre verwendung ATE479662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200410101710 2004-12-23
PCT/CN2005/002293 WO2006066512A1 (fr) 2004-12-23 2005-12-23 Dérivés de pyrimidinone, leur synthèse et leurs applications

Publications (1)

Publication Number Publication Date
ATE479662T1 true ATE479662T1 (de) 2010-09-15

Family

ID=36601393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824250T ATE479662T1 (de) 2004-12-23 2005-12-23 Pyrimidinonverbindungen, ihre herstellung und ihre verwendung

Country Status (10)

Country Link
US (1) US7872012B2 (de)
EP (1) EP1845092B1 (de)
JP (1) JP4864009B2 (de)
CN (1) CN101098859B (de)
AT (1) ATE479662T1 (de)
AU (1) AU2005318783B2 (de)
CA (1) CA2591053C (de)
DE (1) DE602005023347D1 (de)
HK (1) HK1109393A1 (de)
WO (1) WO2006066512A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045342A1 (de) * 1980-12-02 1982-07-01 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen Neue substituierte pyrimidin-nukleoside mit antiviraler und cytostatischer wirkung, verfahren zu deren herstellung und daraus bereitete arzneiformen
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5300477A (en) 1992-07-17 1994-04-05 Rohm And Haas Company 2-arylpyrimidines and herbicidal use thereof
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
JP4864009B2 (ja) 2012-01-25
US20080280930A1 (en) 2008-11-13
AU2005318783A1 (en) 2006-06-29
WO2006066512A1 (fr) 2006-06-29
DE602005023347D1 (de) 2010-10-14
US7872012B2 (en) 2011-01-18
EP1845092A4 (de) 2008-09-17
HK1109393A1 (en) 2008-06-06
EP1845092A1 (de) 2007-10-17
AU2005318783B2 (en) 2009-04-09
CN101098859B (zh) 2013-03-06
EP1845092B1 (de) 2010-09-01
CA2591053A1 (en) 2006-06-29
JP2008525326A (ja) 2008-07-17
CN101098859A (zh) 2008-01-02
CA2591053C (en) 2011-03-15

Similar Documents

Publication Publication Date Title
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
WO2006027346A3 (en) Novel pyrazolopyrimidines
FR21C1031I1 (de)
WO2007056771A3 (en) Compounds for the treatment of metabolic disorders
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
ATE476422T1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
ATE530519T1 (de) Cyclobutylaminderivate
DE602006012801D1 (de) Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino-propylaminen, 3-benzyl-3 hydroxy-2-amino-propionsäureamiden und verwandten verbindungen als analgetika
WO2007100880A8 (en) Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
DE602005013923D1 (de) Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
ATE495673T1 (de) Stabilisierte enzymzusammensetzungen
DE602005010821D1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
BRPI0615272A2 (pt) inibidores de p38 map kinase e métodos para uso dos mesmos
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
ATE479662T1 (de) Pyrimidinonverbindungen, ihre herstellung und ihre verwendung
WO2005077906A8 (en) Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
DK2359826T3 (da) Kombination af HMG-reduktaseinhibitor rosuvastatin med en phosphodiesterase-4-inhibitor, såsom roflumilast, roflumilast-N-oxid til behandlingen af inflammatoriske pulmonale sygdomme
WO2007059116A3 (en) Geldanamycin derivatives and pharmaceutical compositions thereof
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
ATE488513T1 (de) 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties